Tarsus Pharmaceuticals, Inc. ( TARS ) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -45.45% and +9.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
IRVINE, Calif., July 30, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( NASDAQ: TARS ) , today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update.
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( NASDAQ: TARS ) , today announced that management plans to participate in the following upcoming investor conferences: ...
Tarsus to Participate in Upcoming Investor Conferences - Tarsus Pharmaceuticals ( NASDAQ:TARS )
IRVINE, Calif., May 29, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. TARS, today announced that management plans to participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 6:00 a.m. PT / 8:00 a.m. CT
Tarsus Pharmaceuticals ( TARS ) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Tarsus to Participate in Upcoming Investor Conferences - Tarsus Pharmaceuticals ( NASDAQ:TARS )
IRVINE, Calif., May 08, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. TARS today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, at 3:40 p.m. PT / 6:40 p.m. ET
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal - Elanco Animal Health ( NYSE:ELAN ) , Tarsus Pharmaceuticals ( NASDAQ:TARS )
Elanco to cut net leverage ratio to 3.9x-4.3x EBITDA by end of 2025 using $295 million from Blackstone. Deal reduces interest expense by $10 million; U.S. royalties sold apply to sales between Apr 2025 and Aug 2033. Feel unsure about the market's next move?
Tarsus Pharmaceuticals, Inc. ( TARS ) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 7.25% and 8.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
CI's first-quarter results are likely to have benefited from growing pharmacy revenues and fees.
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals ( TARS ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Earnings Preview: Werewolf Therapeutics, Inc. ( HOWL ) Q1 Earnings Expected to Decline
Werewolf Therapeutics (HOWL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
IRVINE, Calif., April 24, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( NASDAQ: TARS ) , today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update.
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - Tarsus Pharmaceuticals ( NASDAQ:TARS )
IRVINE, Calif., April 24, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. TARS, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update.
Universal Health to Report Q1 Earnings: Can it Surprise Wall Street?
UHS' first-quarter earnings are likely to have benefited from growing admissions and patient days.
HCA Healthcare to Report Q1 Earnings: Key Estimates to Note
HCA's first-quarter earnings are likely to have benefited from growing admissions.
Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch
MOH's first-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery ( ASCRS ) 2025 Annual Meeting - Tarsus Pharmaceuticals ( NASDAQ:TARS )
IRVINE, Calif., April 22, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc.
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery...
IRVINE, Calif., April 22, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( NASDAQ: TARS ) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® ( lotilaner ophthalmic solution ) ...
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery ( ASCRS ) 2025 Annual Meeting
IRVINE, Calif., April 22, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( NASDAQ: TARS ) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® ( lotilaner ophthalmic solution ) ...
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
IRVINE, Calif., March 12, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( Nasdaq: TARS ) ( the "Company" or "Tarsus" ) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share.
Tarsus Announces Proposed $100.0 Million Public Offering - Tarsus Pharmaceuticals ( NASDAQ:TARS )
IRVINE, Calif., March 12, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. TARS ( the "Company" or "Tarsus" ) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock.
Tarsus Announces Proposed $100.0 Million Public Offering
IRVINE, Calif., March 12, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( Nasdaq: TARS ) ( the "Company" or "Tarsus" ) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock.
Tarsus to Participate in Upcoming Investor Conference
IRVINE, Calif., March 06, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( NASDAQ: TARS ) , today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET.
Tarsus Pharmaceuticals, Inc. ( TARS ) Reports Q4 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 11.76% and 12.33%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
IRVINE, Calif., Feb. 20, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( NASDAQ: TARS ) , today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a ...
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 - Tarsus Pharmaceuticals ( NASDAQ:TARS )
IRVINE, Calif., Feb. 20, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. TARS, today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update.
Molina Healthcare to Report Q4 Earnings: What Do the Estimates Say?
MOH's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Tarsus to Participate in Upcoming Investor Conferences - Tarsus Pharmaceuticals ( NASDAQ:TARS )
IRVINE, Calif., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. TARS, today announced that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ET
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. ( NASDAQ: TARS ) , today announced that management will participate in fireside chats at two upcoming investor conferences: ...
Can Centene's Q4 Earnings Navigate Through Rising Medical Costs?
CNC's fourth-quarter earnings are likely to have benefited from growing Commercial business.
Rising Medical Costs to Affect Cigna Q4 Earnings? Check Estimates Here
CI's fourth-quarter results are likely to have benefited from growing premiums and pharmacy revenues.
CRISPR Therapeutics ( CRSP ) Moves 6.5% Higher: Will This Strength Last?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals ( TARS ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
Advancing TP-04 ( lotilaner ophthalmic gel ) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy. Initiation of Phase 2 study planned for ...
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care - Tarsus Pharmaceuticals ( NASDAQ:TARS )
Advancing TP-04 ( lotilaner ophthalmic gel ) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025 Management to host webcast on Tuesday, January 14, 2025, at 8:00 a.m. P.T. / 11:00 ...
Strength Seen in Novavax ( NVAX ) : Can Its 10.9% Jump Turn into More Strength?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.
Wall Street Analysts Think Tarsus Pharmaceuticals ( TARS ) Could Surge 26.98%: Read This Before Placing a Bet
The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Tarsus Pharmaceuticals ( TARS ) Could Rally 41.09%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday - Walt Disney ( NYSE:DIS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs boosted the price target for Tarsus Pharmaceuticals, Inc. TARS from $36 to $41.
Tarsus Pharmaceuticals, Inc. ( TARS ) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes ...
2seventy bio, Inc. ( TSVT ) Reports Q3 Loss, Lags Revenue Estimates
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -28.57% and 33.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Tarsus Pharmaceuticals, Inc. ( TARS ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 - Tarsus Pharmaceuticals ( NASDAQ:TARS )
IRVINE, Calif., Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. TARS, whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m.
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer - Tarsus Pharmaceuticals ( NASDAQ:TARS )
IRVINE, Calif., Nov. 05, 2024 ( GLOBE NEWSWIRE ) -- Tarsus Pharmaceuticals, Inc. TARS, whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, ...
Tarsus Pharmaceuticals ( TARS ) Surges 10.6%: Is This an Indication of Further Gains?
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Koninklijke Philips ( NYSE:PHG )
Shares of LENZ Therapeutics, Inc. LENZ rose sharply in today's pre-market trading. CORXEL and LENZ Therapeutics revealed topline data from China Phase 3 Presbyopia trial of LNZ100. LENZ Therapeutics shares jumped 18% to $31.88 in the pre-market trading session.
Amicus Therapeutics ( FOLD ) Stock Jumps 14.0%: Will It Continue to Soar?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
